Clinsync Clinical Research Profile
Key Indicators
- Authorised Capital ₹ 6.00 Cr
as on 06-07-2024
- Paid Up Capital ₹ 4.39 Cr
as on 06-07-2024
- Company Age 13 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.26 Cr
as on 06-07-2024
- Satisfied Charges ₹ 4.56 Cr
as on 06-07-2024
- Revenue 136.85%
(FY 2022)
- Profit 116.01%
(FY 2022)
- Ebitda 473.33%
(FY 2022)
- Net Worth 17.06%
(FY 2022)
- Total Assets 14.23%
(FY 2022)
About Clinsync Clinical Research
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 6.00 Cr and a paid-up capital of Rs 4.39 Cr.
The company currently has active open charges totaling ₹2.26 Cr. The company has closed loans amounting to ₹4.56 Cr, as per Ministry of Corporate Affairs (MCA) records.
Attili Suresh, Koteswara Sripathipanditaradhyula, and Sandhya Nandiraju serve as directors at the Company.
- CIN/LLPIN
U73200TG2011PTC073413
- Company No.
073413
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Mar 2011
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Clinsync Clinical Research?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Attili Suresh  | Director | 21-Mar-2011 | Current |
| Koteswara Sripathipanditaradhyula | Director | 30-Nov-2020 | Current |
| Sandhya Nandiraju | Whole-Time Director | 08-Jan-2018 | Current |
Financial Performance of Clinsync Clinical Research.
Clinsync Clinical Research Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 136.85% increase. The company also saw a substantial improvement in profitability, with a 116.01% increase in profit. The company's net worth Soared by an impressive increase of 17.06%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Clinsync Clinical Research?
In 2021, Clinsync Clinical Research had a promoter holding of 33.45% and a public holding of 66.56%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 26 Apr 2021 | ₹2.50 M | Open |
Others Creation Date: 10 Mar 2017 | ₹1.00 Cr | Open |
Others Creation Date: 31 Dec 2016 | ₹1.01 Cr | Open |
How Many Employees Work at Clinsync Clinical Research?
Clinsync Clinical Research has a workforce of 147 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Clinsync Clinical Research, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Clinsync Clinical Research's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
